immune thrombocytopenia
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients receiving corticosteroids, IVIG or TPO receptor agonists are allowed to participate. ;- Age minimal 18 years, both men and women - Subjects with primary/chronic ITP (as defined by [Rodeghiero] with platelet numbers that have been below
Exclusion criteria
Exclusion criteria: - Prior treatment with rituximab as this will interfere with B-cell isolation - Use of anticoagulants (e.g. NSAIDs) affecting platelet function - Inadequate renal and liver function, i.e. creatinine or bilirubin >2.5 x the upper normal value - Severe cardiac dysfunction - Severe pulmonary dysfunction - Severe neurological or psychiatric disease - Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol - Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, hypertension, cancer, etc.) - Neutrophil count
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One of the primary results will include platelet properties as described in the study design. Investigation will involve receptor expression on the thrombocytes and functional properties via aggregation tests. The other primary result will be the characterization of patient autoantibodies, and successful isolation of mononuclear cells and subsequent selection of platelet-reactive B-cells. | — |
Countries
Netherlands
Outcome results
None listed